See more : Genasys Inc. (GNSS) Income Statement Analysis – Financial Results
Complete financial analysis of ANI Pharmaceuticals, Inc. (ANIP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ANI Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Western Mining Co.,Ltd. (601168.SS) Income Statement Analysis – Financial Results
- Atam Valves Limited (ATAM.BO) Income Statement Analysis – Financial Results
- Zinzino AB (publ) (ZNZNF) Income Statement Analysis – Financial Results
- Founder SPAC (FOUNU) Income Statement Analysis – Financial Results
- Kohnan Shoji Co., Ltd. (7516.T) Income Statement Analysis – Financial Results
ANI Pharmaceuticals, Inc. (ANIP)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.anipharmaceuticals.com
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 486.82M | 316.39M | 216.14M | 208.48M | 206.55M | 201.58M | 176.84M | 128.62M | 76.32M | 55.97M | 30.08M | 2.30M | 435.16K | 2.47M | 1.26M | 3.78M | 493.05K | 14.44M | 258.35K | 77.89K | 65.49K | 2.83M | 1.75M | 2.00 | 1.00 | 123.06K |
| Cost of Revenue | 181.51M | 138.79M | 100.61M | 87.16M | 63.15M | 73.02M | 79.03M | 48.78M | 12.69M | 11.47M | 9.97M | 9.17M | 50.00K | 268.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -24.29K | 0.00 | 0.00 |
| Gross Profit | 305.30M | 177.60M | 115.53M | 121.32M | 143.39M | 128.55M | 97.81M | 79.84M | 63.63M | 44.50M | 20.11M | -6.87M | 385.16K | 2.21M | 1.26M | 3.78M | 493.05K | 14.44M | 258.35K | 77.89K | 65.49K | 2.83M | 1.75M | 24.29K | 1.00 | 123.06K |
| Gross Profit Ratio | 62.71% | 56.13% | 53.45% | 58.19% | 69.42% | 63.77% | 55.31% | 62.07% | 83.37% | 79.50% | 66.84% | -298.44% | 88.51% | 89.14% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 1,214,600.00% | 100.00% | 100.00% |
| Research & Development | 34.29M | 22.32M | 11.37M | 16.00M | 19.81M | 15.39M | 9.07M | 2.91M | 2.87M | 2.68M | 1.71M | 16.89M | 44.18M | 39.71M | 13.68M | 15.79M | 4.75M | 3.86M | 6.41M | 9.16M | 3.69M | 4.79M | 2.14M | 1.89M | 660.59K | 1.40M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.06M | 31.58M | 27.83M | 21.16M | 17.94M | 16.39M | 8.23M | 6.98M | 5.94M | 5.67M | 5.96M | 4.33M | 7.03M | 3.05M | 3.08M | 2.33M | 1.77M | 2.30M | 1.68M | 853.39K | 1.11M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 161.70M | 124.04M | 84.29M | 64.99M | 55.84M | 44.06M | 31.58M | 27.83M | 21.16M | 17.94M | 16.39M | 8.23M | 6.98M | 5.94M | 5.67M | 5.96M | 4.33M | 7.03M | 3.05M | 3.08M | 2.33M | 1.77M | 2.30M | 1.68M | 853.39K | 1.11M |
| Other Expenses | 62.35M | 56.97M | 48.03M | 55.90M | 51.32M | -550.00K | 55.00K | -74.00K | 41.00K | 160.00K | -305.00K | 353.95K | 148.24K | 167.99K | 20.33M | 43.14K | 89.82K | 117.78K | 100.94K | 101.94K | 92.93K | 92.10K | 92.56K | 122.79K | 90.97K | 269.70K |
| Operating Expenses | 258.33M | 203.33M | 143.70M | 136.89M | 126.97M | 93.19M | 68.58M | 53.08M | 30.93M | 24.49M | 19.21M | 25.47M | 51.31M | 45.81M | 39.68M | 21.79M | 9.17M | 11.00M | 9.56M | 12.34M | 6.11M | 6.64M | 4.53M | 3.69M | 1.60M | 2.78M |
| Cost & Expenses | 439.85M | 342.12M | 244.31M | 224.05M | 190.12M | 166.22M | 147.61M | 101.86M | 43.62M | 35.96M | 29.18M | 25.47M | 51.36M | 46.08M | 39.68M | 21.79M | 9.17M | 11.00M | 9.56M | 12.34M | 6.11M | 6.64M | 4.53M | 3.66M | 1.60M | 2.78M |
| Interest Income | 0.00 | 28.05M | 11.92M | 9.45M | 12.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.54K | 8.33K | 12.67K | 11.65K | 588.46K | 1.10M | 428.34K | 401.19K | 250.42K | 86.59K | 63.79K | 174.42K | 227.72K | 0.00 | 0.00 |
| Interest Expense | 26.94M | 28.05M | 11.92M | 9.45M | 12.97M | 14.76M | 12.04M | 11.33M | 11.01M | 787.00K | 467.00K | 348.02K | 681.57K | 688.08K | 147.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 59.79M | 56.97M | 47.25M | 44.64M | 44.61M | 33.74M | 27.93M | 22.34M | 6.90M | 3.88M | 1.11M | 258.95K | 148.24K | 167.99K | 137.28K | 43.14K | 89.82K | 117.78K | 100.94K | 101.94K | 92.93K | 92.10K | 110.56K | 122.79K | 90.97K | 139.77K |
| EBITDA | 106.60M | 48.07M | -1.68M | 29.07M | 60.74M | 69.10M | 57.16M | 56.31M | 39.64M | 24.04M | 7.51M | -27.23M | -50.78M | -45.34M | -47.24M | -17.38M | -7.49M | 3.56M | -9.55M | -11.91M | -5.95M | -3.72M | -2.68M | -3.31M | -1.51M | -2.52M |
| EBITDA Ratio | 21.90% | 10.09% | 6.82% | 13.71% | 29.44% | 34.01% | 32.35% | 38.12% | 51.94% | 42.96% | 5.66% | -995.51% | -11,667.01% | -1,678.41% | -2,330.70% | -475.31% | -1,742.13% | 32.10% | -3,271.24% | -15,618.58% | -9,089.41% | -131.22% | -153.10% | -177,106,050.00% | -151,397,600.00% | -2,047.48% |
| Operating Income | 46.97M | -25.06M | -32.51M | -16.06M | 16.35M | 35.36M | 28.33M | 20.08M | 32.70M | 20.01M | 898.00K | -23.17M | -50.93M | -43.61M | -38.43M | -18.01M | -8.68M | 3.44M | -9.30M | -12.27M | -6.05M | -3.81M | -2.79M | -3.66M | -1.60M | -2.66M |
| Operating Income Ratio | 9.65% | -7.92% | -15.04% | -7.71% | 7.92% | 17.54% | 16.02% | 15.61% | 42.84% | 35.74% | 2.99% | -1,007.14% | -11,703.01% | -1,762.50% | -3,054.36% | -476.45% | -1,760.34% | 23.82% | -3,600.61% | -15,749.47% | -9,231.29% | -134.47% | -159.43% | -183,245,550.00% | -160,494,100.00% | -2,161.05% |
| Total Other Income/Expenses | -27.10M | -27.38M | -16.27M | -9.95M | -13.19M | -15.31M | -11.98M | -11.40M | -10.97M | -627.00K | -772.00K | -5.60M | -681.67K | -2.59M | -9.10M | -17.41B | -7.58B | -1.08M | -348.81K | 250.42K | 86.59K | 0.00 | 174.42K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 19.87M | -62.67M | -56.06M | -25.96M | 3.16M | 20.05M | 16.35M | 8.68M | 21.73M | 19.38M | 126.00K | -27.84M | -51.61B | -46.20B | -47.53B | -17.43B | -7.58B | 2.79B | -9.65B | -12.02M | -5.96M | -3.81M | -2.61M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 4.08% | -19.81% | -25.94% | -12.45% | 1.53% | 9.95% | 9.24% | 6.75% | 28.48% | 34.62% | 0.42% | -1,210.03% | -11,859,661.73% | -1,867,089.37% | -3,777,879.80% | -460,882.47% | -1,538,256.46% | 19,331.99% | -3,735,629.43% | -15,427.94% | -9,099.08% | -134.47% | -149.44% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.09M | -14.77M | -13.46M | -3.41M | -2.94M | 4.56M | 17.43M | 4.74M | 6.36M | -9.37M | 20.00K | -121.79K | 681.67K | 2.59M | 9.10M | -17.41B | -7.58B | 648.49K | 348.81K | 0.00 | 0.00 | 0.00 | 0.00 | -227.72K | -198.68K | 0.00 |
| Net Income | 18.78M | -47.90M | -42.60M | -22.55M | 6.09M | 15.49M | -1.08M | 3.93M | 15.38M | 28.75M | 301.00K | -27.72M | -51.61M | -46.20M | -47.53M | -17.43M | -7.58M | 2.79M | -9.65M | -12.02M | -5.96M | -3.81M | -2.61M | -3.44M | -1.41M | -2.66M |
| Net Income Ratio | 3.86% | -15.14% | -19.71% | -10.82% | 2.95% | 7.69% | -0.61% | 3.06% | 20.14% | 51.36% | 1.00% | -1,204.73% | -11,859.66% | -1,867.09% | -3,777.88% | -460.88% | -1,538.26% | 19.33% | -3,735.63% | -15,427.94% | -9,099.08% | -134.47% | -149.44% | -171,859,750.00% | -140,625,900.00% | -2,161.05% |
| EPS | 0.95 | -2.95 | -3.38 | -1.88 | 0.51 | 1.33 | -0.09 | 0.34 | 1.34 | 2.61 | -0.92 | -7.64 | -18.88 | -25.23 | -50.39 | -22.97 | -10.71 | 4.68 | -17.92 | -25.23 | -19.44 | -18.28 | -14.50 | -21.51 | -10.24 | -27.47 |
| EPS Diluted | 0.94 | -2.95 | -3.38 | -1.88 | 0.50 | 1.32 | -0.09 | 0.34 | 1.32 | 2.59 | -0.92 | -7.64 | -18.88 | -25.23 | -50.39 | -22.97 | -10.71 | 4.68 | -17.92 | -25.23 | -19.44 | -18.28 | -14.50 | -21.51 | -10.24 | -27.47 |
| Weighted Avg Shares Out | 18.00M | 16.26M | 12.60M | 11.96M | 11.84M | 11.68M | 11.55M | 11.45M | 11.37M | 10.94M | 5.07M | 3.63M | 2.73M | 1.83M | 943.11K | 758.54K | 707.93K | 588.64K | 538.67K | 476.26K | 306.63K | 208.42K | 180.15K | 159.82K | 137.29K | 96.83K |
| Weighted Avg Shares Out (Dil) | 18.19M | 16.26M | 12.60M | 11.96M | 12.04M | 11.77M | 11.55M | 11.57M | 11.56M | 11.05M | 5.07M | 3.63M | 2.73M | 1.83M | 943.11K | 758.54K | 707.93K | 596.78K | 538.67K | 476.26K | 306.63K | 208.42K | 180.15K | 159.82K | 137.29K | 96.83K |
ANI Pharmaceuticals, Inc. (ANIP) Q4 2023 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q4 2023 Earnings Call Transcript
Compared to Estimates, ANI (ANIP) Q4 Earnings: A Look at Key Metrics
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance
BAUDETTE, Minn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and full year ended December 31, 2023.
Unveiling ANI (ANIP) Q4 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ANI (ANIP), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
BAUDETTE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Leerink Partners Global Biopharma Conference...
ANI Pharmaceuticals (ANIP) Advances While Market Declines: Some Information for Investors
The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $57.03, representing a +0.92% change from its previous close.
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET
BAUDETTE, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to...
ANI Pharmaceuticals (ANIP) Ascends While Market Falls: Some Facts to Note
The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $56.04, representing a +1.12% change from its previous close.
ANI Pharmaceuticals (ANIP) Rises Yet Lags Behind Market: Some Facts Worth Knowing
ANI Pharmaceuticals (ANIP) reachead $55.02 at the closing of the latest trading day, reflecting a +0.7% change compared to its last close.
Source: https://incomestatements.info
Category: Stock Reports